TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03123016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast 30 mg orally, twice daily. (oral tablet)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NB-UVB phototherapy
Description: treatment with narrowband UVB two to three times weekly to one half of their body for a total of 16 weeks
Study: NCT02489188

Intervention type: PROCEDURE
Intervention: arthroplasty
Description: patients, who are scheduled for arthroplasty, will be measured before and on average 6 months after surgery

Intervention type: PROCEDURE
Intervention: arthroplasty
Description: patients, who are scheduled for arthroplasty, will be measured before and on average 6 months after surgery

Intervention type: PROCEDURE
Intervention: arthroplasty
Description: patients, who are scheduled for arthroplasty, will be measured before and on average 6 months after surgery

Intervention type: OTHER
Intervention: manual therapy
Description: patients, who are scheduled for manual therapy, will be measured before, immediately and on average 1 week after treatment

Intervention type: OTHER
Intervention: manual therapy
Description: patients, who are scheduled for manual therapy, will be measured before, immediately and on average 1 week after treatment
Study: NCT02720692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Study: NCT02489188

Intervention type: OTHER
Intervention: manual therapy
Description: patients, who are scheduled for manual therapy, will be measured before, immediately and on average 1 week after treatment

Intervention type: OTHER
Intervention: manual therapy
Description: patients, who are scheduled for manual therapy, will be measured before, immediately and on average 1 week after treatment
Study: NCT02720692

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Placebo
Study: NCT01740401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: This study consists of a Treatment Period, D1 Zofran 8mg pre-Cyclophosphamide 300mg/mg2 po and D3 Ipilimumab 10mg/kg iv wks 1,4,7 and 10; Tumor assessment at week 12; Follow-Up period weeks 13,16,and 20 with no treatment; Maintenance Period, D1 10mg/kg iv wks 24,36,48 and 60. Week 40=end of treatment; week 60=end of study
Study: NCT03841435

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiotherapy
Description: Radiotherapy Treatment, totaling 15 Gy, will be given in 3 fractions over 2 weeks.
Study: NCT00742716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTA018 Injection
Description: Comparison of different dosages of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTA018 Injection
Description: Comparison of different dosages of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTA018 Injection
Description: Comparison of different dosages of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTA018 Injection
Description: Comparison of different dosages of drug
Study: NCT01105273

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: On days -3 to -1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Beginning on day 4 and continuing until blood counts recover

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/M2 once daily IV on days -6 to -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg IV on day-3 and -2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CD3±CD19 depleted hematopoietic stem cell transplantation
Description: Immunogenetic depletion on CliniMACS
Study: NCT03807414

Intervention type: DEVICE
Intervention: oXiris
Description: Every center will prescribe EBPT with oXiris in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
Study: NCT04153045

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Radiograph interpretation for pulmonary abnormalities
Description: The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiograph interpretation for pulmonary abnormalities
Description: The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis.
Study: NCT06158191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program
Description: Participants will take part in a lifestyle modification program focused on physical activity and diet.
Study: NCT01213979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 500 mg iron isomaltoside 1000
Description: 500 mg iron isomaltoside 1000 given as a bolus injection over 2 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1000 mg iron isomaltoside 1000
Description: 1000 mg iron isomaltoside 1000 given as a infusion over 15 minutes
Study: NCT02891707

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitative Lower-limb Orthopedic Accommodating-feedback Device (ReLOAD)
Description: The study will use a novel piece of technology, the ReLOAD, which is a data collector system that uses instrumented insoles, custom, miniature (1x1) microcontroller with accelerometer, gyroscopes, and geomagnetic sensors connected to a Bluetooth transceiver to collect and transmit gait kinematic data to mobile devices, such as an iPad and iPod. When a person walks or performs a specific activity, the ReLOAD system captures the movement, which can then be stored locally within the mobile device and/or encrypted and sent to a secured central server. This allows the patient or provider to access clinically relevant biomechanical data to help guide rehabilitation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitative Lower-limb Orthopedic Accommodating-feedback Device (ReLOAD)
Description: The study will use a novel piece of technology, the ReLOAD, which is a data collector system that uses instrumented insoles, custom, miniature (1x1) microcontroller with accelerometer, gyroscopes, and geomagnetic sensors connected to a Bluetooth transceiver to collect and transmit gait kinematic data to mobile devices, such as an iPad and iPod. When a person walks or performs a specific activity, the ReLOAD system captures the movement, which can then be stored locally within the mobile device and/or encrypted and sent to a secured central server. This allows the patient or provider to access clinically relevant biomechanical data to help guide rehabilitation.
Study: NCT00952107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLARE imaging system
Description: Testing of operation of imaging system
Study: NCT01817725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV vaccine (Engerix B)
Description: Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) is administered intramuscularly at 0, 2, 4, 6, 8, 10, 12 months. The dosage will be 20μg in those \<= 20 years old and 40μg in those \> 20 years old.
Study: NCT02857452

Intervention type: OTHER
Intervention: SLA Questionnaire

Intervention type: OTHER
Intervention: Lupus Qol Questionnaire
Study: NCT03179397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Model SC9
Description: Experimental
Study: NCT02489188

Intervention type: OTHER
Intervention: manual therapy
Description: patients, who are scheduled for manual therapy, will be measured before, immediately and on average 1 week after treatment
Study: NCT03179397

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Model LI61SE
Description: Active Comparator
Study: NCT02489188

Intervention type: PROCEDURE
Intervention: lumbar spinal stenosis decompression
Description: patients, who are scheduled for lumbar spinal stenosis decompression, will be measured before and on average 6 months after surgery
Study: NCT03487211

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine 30mg PO once daily for 1 week followed by an increase to 60mg PO once daily
Study: NCT05716126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]Iruplinalkib (WX-0593)
Description: Volunteer will receive a single oral dose of 120 mg \[14C\]Iruplinalkib (WX-0593) as a solution on Day 1
Study: NCT03654833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: PARP inhibitor
Study: NCT03487211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 10mg PO once daily for 1 week followed by an increase to 20mg PO once daily
Study: NCT03261453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Elipse Device
Description: Intervention Device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Elipse Sham Device
Description: Control Device
Study: NCT03654833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab & bemcentinib
Description: PD1 checkpoint inhibitor, AXL inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab & Bevacizumab
Description: PDL1 checkpoint inhibitor, VEGF inhibitor
Study: NCT02453503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Licorice
Description: licorice mucoadhesive films evey 6 hours for two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Triamcinolone acetonide mucoadhesive films 1 mg every 6 hours for two weeks.
Study: NCT02737345

Intervention type: OTHER
Intervention: Rotem
Study: NCT01835665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimodipine
Description: Nimodipine is an FDA-approved drug for subarachnoid hemorrhage indication
Study: NCT03654833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab and Niraparib
Description: IG Antibody, PARP Inhibitor
Study: NCT00556868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast/no breakfast
Description: A: Breakfast on the first day of intervention. Fasting (no breakfast) on the second day of intervention.~B: Breakfast on the second day of intervention. Fasting (no breakfast) on the first day of intervention
Study: NCT02610946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic application
Description: Electronic application (app) based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Paper-based
Description: Paper-based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
Study: NCT04406077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ligasure
Description: Using ligasure to treat hydrocele
Study: NCT01790074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TrP therapy
Description: TrP manual therapy comprises different manual approaches, e.g., compression, stretching, or transverse friction massage applied over active TrPs in the sternocleidomastoid muscle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TrP manual control therapy
Description: The treatment consisted of a simulation of the same TrP therapy treatment applied to the experimental group without the application of any therapeutic pressure.
Study: NCT05681598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: The treatment started with a dose of 15mg/kg/day of HU. This initial dose was increased in steps of 5mg/kg/day every three months up to 35mg/kg/day or a maximal tolerated dose.
Study: NCT03073876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Hydrochloride
Description: 5mg of Donepezil Hydrochloride by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil Hydrochloride
Description: 5mg of Donepezil Hydrochloride by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: prepared placebo looking exactly the same as drug. Participants took placebo by mouth for approximately 6 weeks, and after unblinding, they took donepezil hydrochloride for 6 months.
Study: NCT02726659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Adjunct celecoxib
Study: NCT01629459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise and protein supplementation
Description: Resistance exercise training will occur 3x/wk for 12 wks at a physical therapy or cardiac rehabilitation facility near the participant's home. Participant will take 42 grams of supplementation protein daily.
Study: NCT04764227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw\*5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC=2, ivgtt, d1, qw\*5

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 1.8Gy/d, d1-5/week, 28Fx
Study: NCT02726659

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Adjunct placebo
Study: NCT03347201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HMS Plus
Description: Subjects randomized to the intervention group will have their dose of Heparin and Protamine calculated by the HMS Plus.
Study: NCT00079716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-40 (anti-huCD40 mAb)
Description: 0.5-8 mg/kg IV (in the vein) on Day 1; 0-8 mg/kg on Day 4; 0.5-16 mg/kg on Days 8 and 15; 0-16 mg/kg on Day 29.
Study: NCT00358436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide
Description: Aclidinium bromide 200 μg once-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
Study: NCT00305539

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 40 mg sc / for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04897880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat capsules, 10mg, starting at a de-escalated dose of 8mg/m2 per day
Study: NCT03248427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib flat-fixed dose of 600 mg daily (three 200-mg capsules), days 1 to 21 of a 28-days cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Daily continuous
Study: NCT04897880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat capsules, 10mg, starting at a de-escalated dose of 8mg/m2 per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat capsules, 10mg, starting at a de-escalated dose of 8mg/m2 per day
Study: NCT03248427

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: 60 mg/m2 as a continuous IV perfusion

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: 600 MG/M2 in a 30 minutes IV infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: 80 mg/m2, in one hour IV infusion
Study: NCT04435028

Intervention type: DRUG
Intervention: Ketotifen 1 MG
Description: Ketotifen is added to patients on anthracycline-containing chemotherapy for 6 months

Intervention type: DRUG
Intervention: Ketotifen 1 MG
Description: Ketotifen is added to patients on anthracycline-containing chemotherapy for 6 months
Study: NCT02180048

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 400 mg of caffeine/day (Two 200mg pills/day)
Description: One phase of treatment will have participants consume two 200 mg-caffeine pills day (total of 400 mg of caffeine/ d) for 7 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 200 mg of caffeine/day (One 200mg pill and one placebo pill)
Description: This arm will receive one 200 mg caffeine pill and one sugar pill (placebo pill)
Study: NCT02272374

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AVF creation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AVF creation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TCC placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TCC placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AVG creation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AVG creation
Study: NCT03408613

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure
Description: See arm/group description
Study: NCT02180048

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Two placebo pills/day
Description: This arm will have participants consume two placebo pills each day.
Study: NCT03408613

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supplemental Oxygen
Description: See arm/group description

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: See arm/group description
Study: NCT02531529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomedine
Description: intraoperative infusion

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Fentanyl
Study: NCT02068313

Intervention type: RADIATION
Intervention: Toxicity and outcome measures of IMRT
Study: NCT04040556

Intervention type: OTHER
Intervention: Simulation class
Description: Pediatric anesthesia simulation class for anesthesia residences
Study: NCT00652951

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™)
Description: Intramuscular injection, 3 doses in the primary vaccination and 1 dose in the booster vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™)
Description: Intramuscular injection, 3 doses in the primary vaccination and 1 dose in the booster vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ hexa.
Description: Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
Study: NCT06138912

Intervention type: RADIATION
Intervention: plain radiography (x-ray)
Description: Radiographic imaging of the subjects was performed, and anteroposterior, lateral, flexion-extension, and right-left lateral bending radiograph views were obtained

Intervention type: RADIATION
Intervention: plain radiography (x-ray)
Description: Radiographic imaging of the subjects was performed, and anteroposterior, lateral, flexion-extension, and right-left lateral bending radiograph views were obtained
Study: NCT03853915

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18-F]- FDG - PET
Description: \[F-18\]-FDG Injection is an intravenous diagnostic radiopharmaceutical used for Positron Emission Tomography. While this is not the subject of investigation in this study, \[F-18\]-FDG will be used in the PET imaging assessment of study participants during their 3 month follow-up post-treatment.
Study: NCT01654692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab and Fotemustine
Description: Ipilimumab: 10 mg/kg q3 weeks for 4 doses, q12 weeks starting at Week 24 Fotemustine: 100 mg/m2 q1 week for 3 doses, q3 weeks starting at Week 9
Study: NCT00652951

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediacel™
Description: Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
Study: NCT00440362

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX502
Description: 1 dose at 2e8 IU given at t=0 via IM route

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX502
Description: 1 dose at 2e7 IU given at T=0 via the IM route

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX502
Description: 1 dose at 2e7 IU given at t=0 via the SC route

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX502
Description: 1 dose at 2e8 IU given at T=0 via the SC route
Study: NCT00652951

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediacel™
Description: Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar™
Description: Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
Study: NCT01508780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: St Jude Medical C7 Dragonfly Optical Coherence Tomography (OCT)
Description: All subjects will have OCT and IVUS imaging during their right heart catheterization.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific Intravascular Ultrasound
Description: All subjects will have OCT and IVUS imaging during their right heart catheterization.
Study: NCT02107599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetapir (18F)
Description: No Florbetapir (18F) will be administered in this study.
Study: NCT00440362

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX502
Description: 2 doses at 2e7 IU given at T=0 and 8 weeks via the IM route